Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 1;107(4):991-995.
doi: 10.3324/haematol.2021.280080.

Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center

Dan Liu  1 , Zefeng Xu  1 , Peihong Zhang  2 , Tiejun Qin  1 , Xiujuan Sun  3 , Shiqiang Qu  1 , Lijuan Pan  1 , Jiao Ma  2 , Wenyu Cai  2 , Jinqin Liu  3 , Huijun Wang  2 , Qi Sun  2 , Zhongxun Shi  1 , Huijun Huang  1 , Gang Huang  4 , Robert Peter Gale  5 , Bing Li  6 , Raajit K Rampal  7 , Zhijian Xiao  8
Affiliations

Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center

Dan Liu et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Comparison of hematologic and molecular responses between the interferon and hydroxyurea cohorts. (A) Hematologic responses, (B) complete hematologic remission (CHR) rates over time, (C) molecular responses, and (D) dynamics of JAK2 V617F variant allele frequencies (VAF) over time are compared between the interferon (IFN) and hydroxyuera (HU) cohorts. In (D) the horizontal lines indicate median values; bars represent minimum and maximum values; boxes represent values included between the 25% and 75% percentiles. (E) JAK2v V617F VAF waterfall plot in the IFN (n=22) and HU (n=31) cohorts; the y-axis indicates the absolute change of the JAK2 V617F VAF from baseline to the best molecular response; each bar represents a patient; dotted lines represent median changes of the JAK2 V617F VAF in each group. IFN: conventional (non-pegylated) interferon; HCT: hematocrit; PLT: platelet; WBC: white blood cell; PMR: partial molecular response; Pts: patients. *P<0.05; **P<0.01; ***P<0.001.
Figure 2.
Figure 2.
Comparison of hematologic and molecular responses between the interferon and hydroxyurea cohorts stratified by thrombosis risk. Hematologic (A) and molecular (B) responses of low-risk patients. Hematologic (C) and molecular (D) responses of high-risk patients. IFN: interferon; HU: hydroxyurea; RBC: red blood cell; WBC: white blood cell; HCT: hematocrit; PLT: platelet; VAF: variant allele frequency; IQR: interquartile range; *JAK2 V617F VAF in JAK2 V617F-mutated patients; CHR: complete hematologic remission; PMR: partial molecular response. *P<0.05; **P<0.01; ***P<0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Grinfeld J, Nangalia J, Baxter EJ, et al. . Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416-1430. - PMC - PubMed
    1. Leukemia and Lymphoma Group Chinese Society of Hematology Chinese Medical Association. [Chinese expert consensus on the diagnosis and treatment of polycythemia vera (2016)]. Zhonghua Xue Ye Xue Za Zhi. 2016;4(4):265-268. - PMC - PubMed
    1. Arber DA, Orazi A, Hasserjian R, et al. . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. - PubMed
    1. Tashi T, Swierczek S, Kim SJ, et al. . Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. Leukemia. 2018;32(8):1830-1833. - PMC - PubMed
    1. Barosi G, Mesa R, Finazzi G, et al. . Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778-4781. - PMC - PubMed

Publication types